Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Front Oncol, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Hyytiäinen A +6 more
europepmc +3 more sources
Journal of Hematology & Oncology, 2016 Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu +5 more
doaj +2 more sources
Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma [PDF]
Frontiers in Pharmacology, 2016 Background: Angiogenesis inhibitors have become an important therapeutic approach in the treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of angiogenesis of Sorafenib in increasing overall survival of patients with HCC is a fundamental element of the treatment of this disease. Considering the heterogeneous aspects of HCC
Berretta M. +7 more
openaire +8 more sources
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Marine Drugs, 2013 Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities.
Ying-Qing Wang, Ze-Hong Miao
doaj +2 more sources
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. [PDF]
Cell Commun Signal, 2022 Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological ...
Ansari MJ +11 more
europepmc +2 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis. [PDF]
J Ovarian Res, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Zhang C, Zhao W.
europepmc +2 more sources
Angiogenesis Inhibitors in Small Cell Lung Cancer. [PDF]
Front Oncol, 2021 Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung ...
Montanino A +14 more
europepmc +2 more sources
Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. [PDF]
Front Oncol, 2021 Background Recent research has shown that selected patients with initially unresectable hepatocellular carcinoma (HCC) are able to achieve conversion to resectable disease through systemic or local therapy.
Zhang J +6 more
europepmc +2 more sources
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. [PDF]
IJU Case Rep, 2020 Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hagimoto H +8 more
europepmc +2 more sources